American Society of Hematology

ASH is the leader in representing the interests of scientists and clinicians working in the field of hematology on Capitol Hill and within federal agencies concerned with the study and treatment of blood-related diseases.

SCD Initiative 

Sickle Cell Disease Initiative

A multi-faceted initiative to identify the highest priority actions needed to improve the outcomes for individuals with SCD in the U.S. and globally.

Fight for Hematology 

Advocacy Leadership Institute

Provides opportunities to learn more about advocacy, health policy, and the legislative process, and to become engaged in the Society’s activities.

CAC Networking Meeting

Learn about the yearly ASH-ASCO Carrier Advisory Committee (CAC) Network Meeting.

Congressional Fellowship

Provides education about the policy making process, including Congress’ relationship to the hematology community.

MACRA Resources

Get an overview of the Medicare Access and CHIP Reauthorization Act (MACRA) and its impact on hematology.

Drug Access Issues

Keep informed of newly approved therapies, safety and prescription matters, and shortages of critical hematologic drugs.

  • Contact Congress to Support NIH Funding and Finish FY 2020 Appropriations

    Fiscal year (FY) 2020 spending bills have stalled in Congress, forcing the passage of a second continuing resolution (CR) to extend FY 2019 funding for federal programs and agencies and allow the government to remain open. Congress is working NOW to attempt to reach an agreement on FY 2020 funding for the National Institutes of Health (NIH) and other federal programs and ASH needs your help to urge lawmakers to finish the FY 2020 appropriations process.

  • Tell Congress to Support NIH Funding for FY 2020

    The Society needs the help of all its members to urge lawmakers to support the robust, sustained, and predictable funding increases for NIH that are currently proposed in the House Labor-HHS spending bill. You can help spread this message by quickly sending an email to your legislators.

  • Urge Your Elected Officials to Provide Dedicated Funding for SCD Data Collection

     As the appropriations process continues in the House of Representatives and Senate for fiscal year (FY) 2020, ASH is working hard to expand key sickle cell disease (SCD) programs within the Centers for Disease Control and Prevention (CDC).  


  • Write Your New Jersey Legislators to Support Patients' Access to Care

    Legislation has been introduced in the New Jersey Legislature that would ensure that patients have access to the life-saving medication that is prescribed to them by their physicians.  S. 1865 will place maximums on the out-of-pocket (OOP) costs that patients can be required to pay for each prescription medication, regardless of the disease. The legislation caps patient OOP costs for prescription medications within state regulated plans and would dramatically improve affordability for patients without significantly altering the existing insurance marketplace. This bill has already passed the New Jersey Assembly by a vote of 77-1 but must now be considered in the state Senate. Your help is needed to urge your state senator to give S. 1865 a hearing and vote during this legislative session.

View all action alerts
  • CAR T-cell Therapy: An Update on Coverage and Reimbursement

    ASH continues to advocate for adequate coverage and reimbursement for chimeric antigen receptor T-cell (CAR-T) therapy. In early August, the Centers for Medicare and Medicaid Services (CMS) finalized policies impacting both reimbursement of and coverage for CAR-T therapy. The final Inpatient Prospective Payment System (IPPS) rule, published on August 2, and the final Decision Memo for CAR T-cell Therapy for Cancers, issued August 7.

  • 2018 ASH Advocacy Activities

    ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.

  • 2018 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait

    ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.

  • 2018 ASH Advocacy Efforts to Ensure Patient Access to Care

    In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.

View all policy news
View all testimony
back to top